RESUMEN
Authors report on a case of a 46-year-old woman, as a rare complication of anticoagulant therapy. Rupture of giant haemangioma of the liver developed after Syncumar treatment. They describe the successful resection of the ruptured tumor, which caused haemorrhagic shock. Based on the review of the literature the authors are the first in Hungary to report on an urgent resection of haemangioma in adult.
Asunto(s)
Acenocumarol/efectos adversos , Hemangioma Cavernoso/inducido químicamente , Neoplasias Hepáticas/inducido químicamente , Femenino , Hemangioma Cavernoso/diagnóstico por imagen , Hemangioma Cavernoso/cirugía , Hepatectomía/métodos , Humanos , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/cirugía , Persona de Mediana Edad , Rotura Espontánea/complicaciones , Rotura Espontánea/cirugía , Choque Hemorrágico/etiología , UltrasonografíaRESUMEN
A double blind study. Antioxidant and antiperoxidative effects of the free radical scavenger agent silymarin (Legalon) were investigated in patients with chronic alcoholic liver disease in a double blind clinical trial. Six month treatment (at a daily dose of 420 mg) with silymarin significantly enhanced the originally low superoxide dismutase activity of erythrocytes and lymphocytes and also restored the diminished superoxide dismutase expression on lymphocytes as measured by flow-cytofluorimetry. In addition, silymarin therapy markedly increased the serum level of ree--SH groups and the activity of glutathione peroxidase. In contrast, a considerable fall in serum malondialdehyde concentration was detected in patients having received silymarin. However, in case of placebo-treated patients the above mentioned parameters of antioxidant defense system and lipid peroxidation failed to change significantly. These data indirectly suggest that antioxidant, antiperoxidative effects might be important factors in the mechanism of hepatoprotective action of silymarin.
Asunto(s)
Flavonoides/farmacología , Peroxidación de Lípido/efectos de los fármacos , Hepatopatías Alcohólicas/tratamiento farmacológico , Oxidación-Reducción/efectos de los fármacos , Silimarina/farmacología , Método Doble Ciego , Humanos , Silimarina/uso terapéuticoRESUMEN
The effects of silymarin (Legalon) therapy on liver function tests, serum procollagen III peptide level and liver histology were studied in 36 patients with chronic alcoholic liver disease in a six month double blind clinical trial. During silymarin treatment serum bilirubin, aspartate aminotransferase and alanin-aminotransferase values have been normalized, while gamma-glutamyl transferase activity and procollagen III peptid level decreased. The changes were significant, and there was a significant difference between post-treatment values of the two groups, as well. In the placebo group only gamma-glutamyl transferase values decreased significantly but to a lesser extent than that in the silymarin group. The histological alterations showed an improvement in the silymarin group, while remained unchanged in the placebo group. These results indicate that silymarin exerts hepatoprotective activity and is able to improve liver functions in alcoholic patients.
Asunto(s)
Flavonoides/uso terapéutico , Hepatopatías Alcohólicas/tratamiento farmacológico , Ensayos Clínicos Controlados Aleatorios como Asunto , Silimarina/uso terapéutico , Enfermedad Crónica , Método Doble Ciego , Evaluación de Medicamentos , Humanos , Hígado/efectos de los fármacos , Hígado/enzimología , Hígado/patología , Hepatopatías Alcohólicas/enzimología , Hepatopatías Alcohólicas/patología , Pruebas de Función Hepática , Procolágeno/sangre , Silimarina/farmacología , Transaminasas/sangre , gamma-Glutamiltransferasa/sangreRESUMEN
The effects of the hepatoprotective, antioxidant drug silymarin (Legalon) on some cellular immune parameters of patients with histologically proven chronic alcoholic liver disease were studied in a six month double blind study. The lectin induced proliferative activity of the lymphocytes got enhanced, the originally low T cell percentage and the originally high CD8+ cell percentage have been normalized, the antibody-dependent and natural cytotoxicity of the lymphocytes decreased during silymarin therapy. All these changes were significant, while in the placebo group no significant changes occurred, except for a moderate elevation of the T cell percentage. Thus, the immunomodulatory activity of silymarin might be involved in the hepatoprotective action of the drug and improves the depressed immunoreactivity of the patients.